(RMIT University) The project team will combine 3-D printing, robotic surgery and advanced manufacturing to create tailored implants for patients with bone cancer, dramatically improving patient and healthcare outcomes.
MicroRNA‑106a regulates the proliferation and invasion of human osteosarcoma cells by targeting VNN2.
Oncol Rep. 2018 Jul 26;:
Authors: Chen Y, Huang T, Yang X, Liu C, Li P, Wang Z, Zhi S
MicroRNAs (miRs) serve an essential role in tumorigenesis and are able to act as tumor suppressor genes or oncogenes. miR‑106a has been identified generally as an oncogene in multiple types of human cancer; however, its association with osteosarcoma has not previously been understood. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to detect miR‑106a expression in 18 …
ConclusionsSNHG1 represents promising novel biomarkers for various cancer types and have a great potential to be effectively used in clinical practice in the near future.
(Massachusetts General Hospital) A Massachusetts General Hospital research team has used epigenome editing tools to investigate how the genetic abnormality that drives Ewing sarcoma — the second most common bone cancer in children and young adults — unleashes tumor growth.
Conditions: High Grade Ovarian Serous Adenocarcinoma; Oligometastasis; Ovarian Carcinosarcoma; Pancreatic Ductal Adenocarcinoma; Recurrent Malignant Neoplasm; Recurrent Osteosarcoma; Recurrent Ovarian Carcinoma; Refractory Malignant Neoplasm; Refractory Osteosarcoma; Refractory Ovarian Carcinoma Interventions: Biological: Autologous Tumor Infiltrating Lymphocytes MDA-TIL; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: In…
ConclusionWe have demonstrated a liquid biopsy-based approach for tracking cancer transcriptomic alterations, which is a promising source of prognostic and therapeutic biomarkers for metastatic OS.Clinical Trial RegistrationNCT03108677.
Dysregulation of repetitive elements has been implicated in many cancers and other human diseases; however, the role of repetitive elements remains largely unexplored. In this issue of Genes &Development, Boulay and colleagues (pp. 1008–1019) explore the ability of GGAA repeats to act as alternative enhancers activated by EWS-FLI1 in Ewing sarcoma and contribute to tumorigenesis. Using CRISPR-mediated epigenome editing, repression of EWS-FLI1 targeted microsatellite enhancers halted aberrant gene expression and impaired the growth of Ewing sarcoma xenografts in vivo. The study reveals the regulatory capacity of r…
Various types of repetitive sequences are dysregulated in cancer. In Ewing sarcoma, the oncogenic fusion protein EWS-FLI1 induces chromatin features typical of active enhancers at GGAA microsatellite repeats, but the function of these sites has not been directly demonstrated. Here, by combining nascent transcription profiling with epigenome editing, we found that a subset of GGAA microsatellite repeats is transcriptionally active in Ewing sarcoma and that silencing individual repeats abolishes local nascent transcription and leads to markedly reduced expression of putative target genes. Epigenome silencing of these repeat …
ConclusionCollectively, our results demonstrate the anti-tumor role of TIPE1 in osteosarcoma and reveal a novel therapy target for osteosarcoma.
Publication date: 1 December 2018Source: Materials Science and Engineering: C, Volume 93Author(s): Iris Bischoff, Roman Tsaryk, Feng Chai, Robert Fürst, Charles James Kirkpatrick, Ronald E. UngerAbstractPatients diagnosed with osteosarcoma are currently treated with intravenous injections of anticancer agents after tumor resection. However, due to remaining neoplastic cells at the site of tumor removal, cancer recurrence often occurs. Successful bone regeneration combined with the control of residual cancer cells presents a challenge for tissue engineering. Cyclodextrins loaded with chemotherapeutic drugs reversibly r…
CONCLUSIONS Our studies suggest a role of GPR110 in tumor progression and as a potential novel prognostic biomarker in osteosarcoma.
PMID: 30052620 [PubMed – in process]